Circulating Extracellular Vesicles from Heart Failure Patients Inhibit Human Cardiomyocyte Activities
Ke Zhen,Xiaojuan Wei,Zelun Zhi,Shiyu Shang,Shuyan Zhang,Yilu Xu,Xiaochuan Fu,Linjia Cheng,Jing Yao,Yue Li,Xia Chen,Pingsheng Liu,Hongchao Zhang
DOI: https://doi.org/10.1007/s12265-024-10571-1
2024-10-11
Journal of Cardiovascular Translational Research
Abstract:Extracellular vesicles (EVs) have been implicated in cardiac remodeling during heart failure (HF). However, the role of circulating EVs (CEVs) in the process of HF is poorly understood. To elucidate the molecular mechanism associated with CEVs in the context of HF, the proteome of 4D label-free EVs from plasma samples was identified. Among the identified proteins, 6 exhibited upregulation while 9 demonstrated downregulation in CEVs derived from HF patients (HCEVs) compared to healthy controls (NCEVs). Our results showed that up-regulated proteins mainly participate in the primary metabolic, glycerolipid metabolic processes, oxidation–reduction process, and inflammatory amplification. In contrast, the down-regulated proteins influenced cell development, differentiation, and proliferation. Compared to NCEVs, HCEVs significantly induced inflammation and triacylglycerol (TAG) accumulation in human cardiomyocytes (HCMs) in vitro. They also compromised their regenerative capacities, triggered endoplasmic reticulum (ER) stress and increased autophagy in HCMs. Further, HCEVs induced differentiation of human cardiac fibroblasts (HCFs), amplifying pro-inflammatory, and pro-fibrotic factors, and enhancing extracellular matrix deposition. Notably, HCEVs are also associated with an increase in the HF biomarker MMP9 within HCFs and demonstrate a negative correlation with autophagic flux. In conclusion, HCEVs appear pivotal in advancing HF via pathological cardiac remodeling.
cardiac & cardiovascular systems,medicine, research & experimental